Direct from blood identification of bloodstream infections in newborns
直接从血液中鉴定新生儿血流感染
基本信息
- 批准号:10674823
- 负责人:
- 金额:$ 99.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-01 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:AccountingAddressAdoptedAdultAffectAntibioticsAntimicrobial ResistanceBiological AssayBirthBloodBlood VolumeBlood specimenBreakthrough deviceBudgetsChicagoChildhoodClinicClinicalClinical MicrobiologyClinical ResearchClinical assessmentsCommunicable DiseasesDNA sequencingDataDetectionDevelopmentDiagnosisDiagnosticDiagnostic EquipmentDiagnostic testsDiseaseEarly DiagnosisEnsureEtiologyEvidence based treatmentExhibitsFeedbackHospitalsHourInfectionInterventionLaboratoriesLifeLive BirthMarketingMedical centerMethodsMolecularMorbidity - disease rateNeonatal MortalityNewborn InfantOutcomePatientsPediatric HospitalsPerformancePhasePopulationPositioning AttributePreparationProcessRegulatory PathwayResistanceResistance developmentRiskSamplingSensitivity and SpecificitySepsisSpecific qualifier valueSpecificityStressSystemTechnologyTemperatureTestingTimeUniversity HospitalsWhole BloodWorkaccurate diagnosisantimicrobialassay developmentcommercializationcostcross reactivitydesigndiagnostic assaydiagnostic platformdiagnostic strategyexperiencein-vitro diagnosticsinnovationinstrumentinstrumentationintrapartummanufacturemanufacturing scale-upmeetingsmembermicrobialmicrobiomemortalityneonatal sepsisneonateoutcome predictionpathogenpathogenic bacteriapathogenic funguspatient populationperformance testsproduct developmentprogramsresistance geneside effectsuccesssystemic inflammatory responsetimeline
项目摘要
PROJECT SUMMARY
Neonatal sepsis is a life-threatening disease that affects 2 out of every 1,000 live births in the US. Caused by an
invasive bloodstream infection (BSI) occurring either at the time of birth or soon thereafter, the disease’s initial
clinical manifestations are often non-specific, variable, at times subtle, and often common to signs of stress. Early
diagnosis followed by appropriate antimicrobial intervention is a key predictor of outcomes. Selection of
appropriate antimicrobials is limited by the current diagnostic process for detection and identification of BSIs
which all rely on primary blood cultures. Cultures are slow, often requiring days to yield a result, and prone to
false-negatives due to maternal antibiotics. In the absence of diagnostic confirmation, treatment is initiated upon
suspicion of sepsis with broad spectrum antibiotics. Unfortunately, this strategy often misses the target and is
associated with side effects, including damage to developing microbiomes. It is therefore critical to advance
innovative diagnostic approaches which do not rely on culturing in order to facilitate accurate diagnosis and
timely transition to evidence-based treatments.
To address this unmet need, HelixBind developed RaPID/neo, a fully automated, sample-to-answer test for
identifying BSIs directly from newborn blood within ~3 hours, without cultures. The test incorporates a broad test
menu of 18 bacterial and fungal pathogens that make up the vast majority of neonatal sepsis cases. RaPID/neo
is implemented on the RaPID (Resistance and Pathogen IDentification) platform, incorporating single-use test
cassettes and a bench top Analyzer. RaPID/neo provides single CFUs/ml sensitivity across its test menu and is
not confounded by polymicrobial infections nor prior antimicrobial treatment. In a preliminary clinical
assessment, RaPID/neo demonstrated >92% sensitivity and 99% specificity across the assay.
In this proposed Direct-to-Phase II project, HelixBind will build on its preliminary data to further product
development by addressing analytical challenges associated with developing a test targeting this vulnerable
patient population. We will review our findings and proposed studies for regulatory clearance with the FDA
during a Pre-Submission process with the agency. Leveraging agency feedback, we will design an in-hospital
study aimed at challenging our clinical studies plan in preparation for the pivotal trials for FDA clearance.
To succeed in this endeavor, we have assembled an accomplished team with expertise in assay development,
instrumentation, consumables manufacturing, clinical microbiology, and infectious disease as well as a
successful track record of commercializing IVD platforms and assays. Together, we will build upon our
preliminary work to complete product development, finalize a regulatory pathway, and challenge the system
with an in-hospital study. Upon completion of this project, we will be well placed to initiate formal Analytical
and Clinical studies for FDA clearance of RaPID/neo.
项目摘要
新生儿败血症是一种危及生命的疾病,在美国每1,000名活产婴儿中就有2名受到影响。造成
侵入性血流感染(BSI)发生在出生时或出生后不久,疾病的初始阶段
临床表现通常是非特异性的、可变的,有时是微妙的,并且通常是压力的共同迹象。早期
诊断后进行适当的抗菌干预是预后的关键预测因素。选择
适当的抗菌剂受到当前用于检测和识别BSI的诊断过程的限制
都依赖于初级血培养培养是缓慢的,通常需要几天才能产生结果,
由于母体抗生素导致的假阴性在没有诊断确认的情况下,治疗开始于
疑似败血症使用广谱抗生素不幸的是,这种策略往往会错过目标,
与副作用有关,包括对发育中的微生物组的损害。因此,至关重要的是
创新的诊断方法,不依赖于培养,以促进准确的诊断,
及时过渡到循证治疗。
为了满足这一未满足的需求,HelixBind开发了RaPID/neo,这是一种全自动的样本到答案测试,
在约3小时内直接从新生儿血液中识别BSI,无需培养。该测试包括一个广泛的测试
18种细菌和真菌病原体构成了新生儿败血症病例的绝大多数。RaPID/neo
在RaPID(耐药性和病原体鉴定)平台上实施,包括一次性测试
试剂卡和台式分析仪。RaPID/neo在其测试菜单中提供单个CFU/ml灵敏度,
未受到多种微生物感染或既往抗菌治疗的混淆。在初步临床试验中,
在评估中,RaPID/neo在整个测定中表现出>92%的灵敏度和99%的特异性。
在这个拟议的直接到第二阶段的项目中,HelixBind将建立在其初步数据的基础上,
通过解决与开发针对这一脆弱群体的测试相关的分析挑战,
患者人群。我们将审查我们的发现和拟议的研究,以获得FDA的监管许可。
在与该机构的预提交过程中。利用机构的反馈,我们将设计一个住院
该研究旨在挑战我们的临床研究计划,为FDA批准的关键试验做准备。
为了在这一奋进中取得成功,我们组建了一个在检测开发方面具有专业知识的成功团队,
仪器仪表、耗材制造、临床微生物学和传染病以及
IVD平台和检测试剂商业化的成功记录。我们将共同努力,
完成产品开发、最终确定监管途径和挑战系统的初步工作
通过一项住院研究。在这个项目完成后,我们将很好地启动正式的分析
以及FDA批准RaPID/neo的临床研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alon Singer其他文献
Alon Singer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alon Singer', 18)}}的其他基金
Commercialization Readiness Pilot (CRP) program support for: Direct-from-specimen identification of pathogens common in endocarditis
商业化准备试点 (CRP) 计划支持: 直接从样本鉴定心内膜炎常见病原体
- 批准号:
10758417 - 财政年份:2023
- 资助金额:
$ 99.13万 - 项目类别:
Diagnostic tool for assessment and tracking of microbial load in bloodstream infections
用于评估和跟踪血流感染中微生物负荷的诊断工具
- 批准号:
10602029 - 财政年份:2023
- 资助金额:
$ 99.13万 - 项目类别:
Direct detection and identification of antimicrobial resistance genes in bloodstream infections
血流感染中抗菌药物耐药基因的直接检测和鉴定
- 批准号:
10680500 - 财政年份:2022
- 资助金额:
$ 99.13万 - 项目类别:
Commercialization Readiness Pilot (CRP) program support for: An Integrated Device for identification of bloodstream infections directly from blood
商业化准备试点 (CRP) 计划支持: 用于直接从血液中识别血流感染的集成设备
- 批准号:
10583448 - 财政年份:2022
- 资助金额:
$ 99.13万 - 项目类别:
Direct from blood identification of bloodstream infections in newborns
直接从血液中鉴定新生儿血流感染
- 批准号:
10477151 - 财政年份:2022
- 资助金额:
$ 99.13万 - 项目类别:
Commercialization Readiness Pilot (CRP) program support for: An Integrated Device for identification of bloodstream infections directly from blood
商业化准备试点 (CRP) 计划支持: 用于直接从血液中识别血流感染的集成设备
- 批准号:
10318834 - 财政年份:2022
- 资助金额:
$ 99.13万 - 项目类别:
Direct detection and identification of antimicrobial resistance genes in bloodstream infections
血流感染中抗菌药物耐药基因的直接检测和鉴定
- 批准号:
10543944 - 财政年份:2022
- 资助金额:
$ 99.13万 - 项目类别:
Massively Multiplexed dsDNA Invasion Arrays
大规模多重 dsDNA 侵袭阵列
- 批准号:
10392969 - 财政年份:2021
- 资助金额:
$ 99.13万 - 项目类别:
Massively Multiplexed dsDNA Invasion Arrays
大规模多重 dsDNA 侵袭阵列
- 批准号:
10599896 - 财政年份:2021
- 资助金额:
$ 99.13万 - 项目类别:
Development of an automated IVD for the ultra-sensitive, direct, molecular detection of Borrelia for early Lyme Disease
开发自动化 IVD,用于对早期莱姆病的疏螺旋体进行超灵敏、直接的分子检测
- 批准号:
10404611 - 财政年份:2020
- 资助金额:
$ 99.13万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 99.13万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 99.13万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 99.13万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 99.13万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 99.13万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 99.13万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 99.13万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 99.13万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 99.13万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 99.13万 - 项目类别:
Research Grant